Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral

08/20/2021 | 06:01am EST


ę MT Newswires 2021
All news about APREA THERAPEUTICS, INC.
01/13APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
01/06Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on T..
AQ
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Biotechnology Index
CI
2021Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant..
AQ
2021Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azaci..
AQ
2021Aprea Therapeutics, Inc. Announces Updated Results from Its Phase 2 Trial Evaluating Ep..
CI
2021APREA THERAPEUTICS : Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Ma..
PU
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Aprea Therapeutics Says FDA Has Removed Its Clinical Hold on Study of Eprenetapopt for ..
MT
2021APREA THERAPEUTICS : FDA Lifts Hold on Eprenetapopt Study in Lymphoid Malignancies
DJ
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -38,2 M - -
Net cash 2021 55,1 M - -
P/E ratio 2021 -1,17x
Yield 2021 -
Capitalization 45,1 M 45,1 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 11
Free-Float -
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 2,10 $
Average target price 4,33 $
Spread / Average Target 106%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars AbrahmsÚn Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-26.83%45
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842